Skip to Main Content

A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

Lobbying disclosures filed on Monday revealed a flurry of pharmaceutical industry activity, including the largest-ever expenditure for the trade group representing pharmacy benefit managers.


The Pharmaceutical Care Management Association spent a record-breaking $1.49 million on lobbying in the first quarter of 2019, the most it has ever spent in a three-month span, according to a STAT analysis of the latest lobbying disclosures. The all-time record comes as the lobbying organization is vocally opposing a Trump administration proposal to ban certain rebates from drug companies to PBMs that could fundamentally threaten the industry’s business model.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • The last most salient reason is for the federal government, especially of the current one, is to not be able to make any decisions for the citizens of our nation.

    The current administration is not in the least concerned about the citizens who are in need of their healthcare issues. Thus it should to be solely between the physicians and their patients.

Comments are closed.